Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out how effective the new combination of the drugs
Capecitabine (Xeloda), Oxaliplatin (Eloxatin), and Irinotecan (Camptosar) are against colon
and rectal cancer. All three of these drugs are approved by the Food and Drug Administration
(FDA) for the treatment of colon or rectal cancer. This however is the first time that these
three drugs have been combined in this schedule for the treatment of colon/rectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute